GlassScriptPhysician profile
Erin D Diskin
NPI 1366042574
$11,677.24
in general payments reported to CMS, 2019-2025
67 companies · $4,484 in 2025
The $4,484 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $909 · 2023: $1,910 · 2024: $4,260 · 2025: $4,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,847 · Education: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,846.52 |
| Education | $807.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $951.14 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $809.75 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Astellas Pharma US INC | $709.66 | 2022-2025 | Padcev, Vyloy, Xtandi |
| Janssen Biotech, INC. | $687.50 | 2022-2025 | Erleada, Rybrevant, Akeega |
| Pfizer INC. | $581.46 | 2023-2025 | |
| Lilly USA, LLC | $562.01 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $538.66 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $475.43 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $407.15 | 2022-2025 | Reblozyl, Opdualag |
| Jazz Pharmaceuticals INC. | $342.05 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $317.45 | 2025 | Provenge |
| Daiichi Sankyo INC. | $308.56 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $305.52 | 2021-2025 | Tukysa, Adcetris |
| Taiho Oncology, INC. | $297.10 | 2023-2025 | |
| Coherus Oncology, INC. | $269.83 | 2024 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $257.16 | 2022-2025 | |
| Beigene USA, INC. | $255.60 | 2024-2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $218.61 | 2022-2025 | Xpovio |
| Eisai INC. | $206.57 | 2022-2025 | |
| Tempus Ai, INC | $206.20 | 2024-2025 | Xt Cdx |
| Beone Medicines USA, INC. | $199.97 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $191.63 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $181.41 | 2024-2025 | Trodelvy |
| Abbvie INC. | $178.73 | 2024-2025 | |
| Tersera Therapeutics LLC | $177.03 | 2022-2025 | Zoladex, Xermelo, Quzyttir |
| Array Biopharma INC | $145.80 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Glaxosmithkline, LLC. | $130.94 | 2022-2025 | Ojjaara, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $114.47 | 2024 | Fruzaqla, Alunbrig |
| Servier Pharmaceuticals LLC | $105.72 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $97.63 | 2021 | |
| Alexion Pharmaceuticals, INC. | $90.91 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $86.22 | 2022-2025 | |
| Puma Biotechnology, INC. | $81.87 | 2022-2025 | Nerlynx |
| Amneal Pharmaceuticals LLC | $76.16 | 2023-2024 | Avastin |
| Stemline Therapeutics INC. | $75.52 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $74.19 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $62.56 | 2024-2025 | Pyrukynd |
| Kyowa Kirin, INC. | $59.02 | 2025 | |
| Aveo Pharmaceuticals, INC. | $57.08 | 2025 | |
| Pharmacosmos Therapeutics INC. | $55.91 | 2023-2024 | Monoferric, Cosela |
| E.R. Squibb & Sons, L.L.C. | $55.75 | 2022-2025 | Opdivo |
| Azurity Pharmaceuticals, INC. | $52.25 | 2024-2025 | Danziten, Vivimusta |
| Geron Corporation | $46.80 | 2025 | Rytelo |
| Novocure INC. | $44.73 | 2025 | Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $40.62 | 2024 | Venclexta, Polivy, Lunsumio |
| Iovance Biotherapeutics, INC. | $35.73 | 2025 | Amtagvi |
| Csl Behring | $34.75 | 2023 | Idelvion, Afstyla |
| Sumitomo Pharma America, INC. | $33.20 | 2024 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $29.86 | 2023 | Imbruvica |
| Tolmar, INC. | $25.55 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $25.55 | 2025 | Rubraca |
| Recordati_rare_diseases_inc. | $25.26 | 2025 | Enjaymo |
| Genmab U.S., INC. | $24.93 | 2023 | Epkinly |
| Spectrum Pharmaceuticals INC. | $21.54 | 2025 | Rolvedon |
| Epizyme, INC. | $19.34 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.13 | 2022 | |
| Amgen INC. | $18.99 | 2022 | |
| Exelixis INC. | $18.85 | 2024 | Cabometyx |
| Foundation Medicine, INC. | $18.73 | 2023 | |
| Progenics Pharmaceuticals, INC. | $18.70 | 2024 | |
| Mirati Therapeutics, INC. | $18.36 | 2023 | Krazati |
| Accord Healthcare, INC. | $18.27 | 2023 | |
| Caris Mpi, INC. | $17.63 | 2025 | Mi Cancer Seek |
| Fennec Pharmaceuticals, INC. | $17.62 | 2024 | Pedmark |
| Verity Pharmaceuticals INC. | $17.29 | 2024 | Trelstar |
| Adc Therapeutics America, INC. | $14.22 | 2023 | |
| G1 Therapeutics, INC. | $13.41 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Diskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.